Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

Eligibility Criteria

• * 1. Adult patients with histologically confirmed distal colorectal adenocarcinoma of any stage.
• 2. Be willing and able to sign the informed consent and comply with study procedures.
• 3. Are scheduled to undergo a SOC colonoscopy for restaging following radiochemotherapy or are scheduled to receive a SOC colonoscopy in the OR prior to resection 4. Have acceptable kidney and liver functions at study entry as evidenced by:
• 9. Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:
• 1. Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or
• 2. Intrauterine device or intrauterine hormone-releasing system. NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above. They are required to maintain abstinence from screening through Day 30, AND Participants in a same sex relationship, must use a barrier form of contraception (e.g., condom, diaphragm) to protect against the transfer of the study drug in any bodily fluids.
• * 1. Pregnant or breastfeeding females 2. They have a known allergy or reaction to ICG, other radiographic contrast agents, or any component of VGT-309.
• 3. Have congenital long QT syndrome or QTcF \> 450ms (males) or \>470ms (females) by history or at Screening ECG.
• 4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.
• 5. Have any other comorbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.